Skip to main content

Month: September 2020

Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents Distributor

EAGAN, Minn., Sept. 22, 2020 (GLOBE NEWSWIRE) — TumorGenesis, a division of Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has received a license for an additional 71 unique ovarian cancer cell lines and now has a total of 96 unique patient derived cells all acquired from ovarian cancer patients. These cell lines were licensed from the English company, Ximbio, the world’s largest non-profit dedicated to life science reagents of all kinds.Richard Gabriel, President of TumorGenesis, commented, “It is remarkable that the UK cancer researchers using the same media mixes now being offered by TumorGenesis for researchers around the world, independently isolated, and identified another unique set...

Continue reading

Freddie Mac Prices $968 Million Multifamily K-Deal, K-F85

MCLEAN, Va., Sept. 22, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) has priced a new offering of Structured Pass-Through Certificates (K Certificates), which includes a class of floating rate bonds indexed to the Secured Overnight Financing Rate (SOFR). The approximately $968 million in K Certificates (K-F85 Certificates) are expected to settle on or about September 30, 2020. The K-F85 Certificates are backed by floating-rate multifamily mortgages with 10-year terms, which are currently LIBOR-based.K-F85 includes one class (Class AL) of senior bonds indexed to LIBOR and another class (Class AS) of senior bonds indexed to SOFR. Freddie Mac will provide a basis risk guarantee on Class AS that covers any floating interest rate basis risk if the value of SOFR exceeds the value of LIBOR.K-F85 PricingDetailsCo-Lead Managers and Joint...

Continue reading

Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen

Company AnnouncementCopenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX® for intravenous administration and, in the United States, as DARZALEX FASPRO™ for subcutaneous administration).The arbitration first is to settle whether Genmab is required to share in Janssen’s royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the subcutaneous formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of subcutaneous daratumumab sales....

Continue reading

Pinnacle Bankshares Corporation and Virginia Bank Bankshares, Inc. Announce Regulatory Approvals for Pending Merger

ALTAVISTA, Va. and DANVILLE, Va., Sept. 22, 2020 (GLOBE NEWSWIRE) — Pinnacle Bankshares Corporation (OTCQX: PPBN) (“Pinnacle” or the “Company”), the holding company for First National Bank, and Virginia Bank Bankshares, Inc. (OTC Pink: VABB) (“Virginia Bank”), the holding company for Virginia Bank and Trust, today jointly announced that they have received all required bank regulatory approvals for the pending merger of Virginia Bank into Pinnacle.“We are extremely pleased to have the approvals from the OCC, the Federal Reserve and the Virginia State Corporation Commission for the merger,” stated Aubrey H. “Todd” Hall, III, Pinnacle’s President and Chief Executive Officer. He further commented, “Together Pinnacle and Virginia Bank will be well positioned to serve our communities and generate enhanced returns for our shareholders....

Continue reading

Aberdeen Acquires Securities in Jourdan

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — ABERDEEN INTERNATIONAL INC. (“Aberdeen” or the “Company”) (TSX: AAB) has acquired 5,000,000 units of Jourdan Resources Inc. (“Jourdan”) (TSX-V: JOR) in a non-brokered private placement financing of Jourdan at a price of $0.015 per unit for a total subscription price of $75,000.     Each unit is comprised of one Jourdan common share and one Jourdan common share purchase warrant.    Each common share purchase warrant is exercisable for one common share of Jourdan at a price of $0.05 for a period of 24 months.Prior to this transaction, Aberdeen owned 8,333,333 common shares of Jourdan, representing approximately 14.2% of the then issued and outstanding shares on a non-diluted basis. As a result of this transaction, Aberdeen owns 13,333,333 Jourdan shares and 5,000,000 Jourdan common share...

Continue reading

Icelandair Group hf.: New Market Making Agreement

Icelandair Group hf. has entered into a new market making agreement with Íslandsbanki hf., whereas the bank undertakes to act as market makers for the Company’s shares in accordance with Article 116 of Act No. 108/2007 on Securities Transactions. The Agreement will become effective when new shares will be issued following the Company’s offering of shares and will replace the Company’s current market making agreements with Íslandsbanki. The main terms of the agreements are as follows:Further information:Eva Sóley Guðbjörnsdóttir, CFOevasoley@icelandair.is

Continue reading

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Blood, a journal of the American Society of Hematology, which highlights interim results of an ongoing Phase 1/2 clinical trial of flotetuzumab in patients with acute myeloid leukemia (AML). Flotetuzumab (also known as MGD006) is an investigational, clinical-stage bispecific DART® molecule that recognizes both CD123 on leukemic cells and CD3 on T cells, with the intended result of T cell mediated killing of leukemic blasts.As described in the article titled “Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia,” 88 AML...

Continue reading

Whitestone REIT Declares Fourth Quarter 2020 Dividends

HOUSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) — Whitestone REIT’s (NYSE:WSR) (“Whitestone” or the “Company”) Board of Trustees has declared a monthly cash dividend of $0.035 per share on the Company’s common shares and operating partnership units. The dividend amount of $0.035 per share represents a quarterly amount of $0.105, and an annualized amount of $0.42 per share. The fourth quarter dividend distribution for 2020 will be as detailed below:Jim Mastandrea, Chairman and Chief Executive Officer commented, “We are pleased to announce Whitestone’s 123rd, 124th, and 125th consecutive monthly dividend distributions. We continue to confirm our commitment to our shareholders by providing attractive-yielding monthly dividends despite the uncertainty in the broader economy. We want to reassure our shareholders that our strategically-chosen...

Continue reading

California Water Service Launches New Smart Landscape Tune-Up Program

SAN JOSE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) — As part of its commitment to help customers control both their water use and their bills, California Water Service (Cal Water) has launched a new Smart Landscape Tune-Up Program for customers in its service areas. This program is available at no charge to customers.Through the Smart Landscape Tune-Up Program, customers can receive a personalized landscape evaluation to identify irrigation leaks, water-saving opportunities, and Cal Water programs that could address high water usage. Additionally, Cal Water is offering repair services, also at no charge, to address leaks or broken equipment found in the evaluation, including valve replacements, drip irrigation repair, and upgrades of broken or leaking sprinklers.“Our promise is to provide quality, service, and value to our customers,...

Continue reading

Astec Industries Announces Investor Day

CHATTANOOGA, Tenn., Sept. 22, 2020 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announces today that it will host an institutional investor and analyst meeting on Thursday, December 10, 2020 from 9:00 AM to 12:00 PM (EST). Presentations from Barry Ruffalo, Chief Executive Officer, and the Astec executive leadership team will be given. The event will also include a question and answer session. The meeting will be held in a virtual-only format to protect the safety of our clients and meeting participants in response to the COVID-19 pandemic and related public health guidance and restrictions.Webcast of PresentationsThe presentation will be available via webcast from 9:00 AM to 12:00 PM Eastern Time and can be obtained at:https://www.webcaster4.com/Webcast/Page/2146/37688About AstecAstec, (www.astecindustries.com), is a...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.